Manuel Hidalgo

Summary

Country: Spain

Publications

  1. ncbi request reprint New insights into pancreatic cancer biology
    M Hidalgo
    Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Ann Oncol 23:x135-8. 2012
  2. doi request reprint Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas
    Manuel Hidalgo
    Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Clin Cancer Res 18:4249-56. 2012
  3. doi request reprint A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer
    Manuel Hidalgo
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Mol Cancer Ther 10:1311-6. 2011
  4. ncbi request reprint Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, School of Medicine, The Johns Hopkins University, The Baunting and Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M89, Baltimore, MD 21231, USA
    Mol Cancer Ther 6:1079-88. 2007
  5. doi request reprint Characterizing DNA methylation patterns in pancreatic cancer genome
    Aik Choon Tan
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Mol Oncol 3:425-38. 2009
  6. ncbi request reprint Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Cancer Res 65:3003-10. 2005
  7. ncbi request reprint Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays
    Belen Rubio-Viqueira
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Mol Cancer Ther 6:515-23. 2007
  8. doi request reprint Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
    Cancer Res 68:2841-9. 2008
  9. doi request reprint A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Mol Cancer Ther 9:311-8. 2010
  10. pmc Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer
    Shinichi Yabuuchi
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Cancer Lett 335:41-51. 2013

Collaborators

Detail Information

Publications78

  1. ncbi request reprint New insights into pancreatic cancer biology
    M Hidalgo
    Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Ann Oncol 23:x135-8. 2012
    ..In this paper, we review the most salient developments in these few areas...
  2. doi request reprint Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas
    Manuel Hidalgo
    Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Clin Cancer Res 18:4249-56. 2012
    ..In this overview, we discuss the implications of biologic understanding of PDA in clinical research and provide insights for future development of novel approaches and agents in this disease...
  3. doi request reprint A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer
    Manuel Hidalgo
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Mol Cancer Ther 10:1311-6. 2011
    ..The data support the use of the personalized tumorgraft model as a powerful investigational platform for therapeutic decision making and to efficiently guide cancer treatment in the clinic...
  4. ncbi request reprint Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, School of Medicine, The Johns Hopkins University, The Baunting and Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M89, Baltimore, MD 21231, USA
    Mol Cancer Ther 6:1079-88. 2007
    ..In addition, the data support the efficacy of combined epidermal growth factor receptor and MAPK inhibitors in biliary and pancreatic cancers, providing the basis to test this combination in the clinic...
  5. doi request reprint Characterizing DNA methylation patterns in pancreatic cancer genome
    Aik Choon Tan
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Mol Oncol 3:425-38. 2009
    ....
  6. ncbi request reprint Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Cancer Res 65:3003-10. 2005
    ....
  7. ncbi request reprint Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays
    Belen Rubio-Viqueira
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Mol Cancer Ther 6:515-23. 2007
    ..Ultimately, an approach of this nature may facilitate the further refinement of patient selection in favor of individuals with molecular profiles, predicting a greater likelihood of therapeutic benefit...
  8. doi request reprint Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
    Cancer Res 68:2841-9. 2008
    ..These results suggest a phenomenon of pathway addiction and support the value of unbiased system biology approaches in drug development...
  9. doi request reprint A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Mol Cancer Ther 9:311-8. 2010
    ..Dynamic interrogation of cancer has the potential to provide key information about mechanisms of resistance and to enhance individualization of treatment...
  10. pmc Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer
    Shinichi Yabuuchi
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Cancer Lett 335:41-51. 2013
    ..In summary, our preclinical data suggest that PF-03084014 has greater anti-tumor activity in combination with gemcitabine in PDA and provides rationale for further investigation of this combination in PDA...
  11. pmc Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer
    Daniel Laheru
    Department of Medical Oncology, Skip Viragh Center for Pancreatic Cancer Research and Patient Care, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room 4M09, Baltimore, MD 21231, USA
    Invest New Drugs 30:2391-9. 2012
    ..This study evaluated the activity, safety, and toxicity of salirasib in preclinical models and patients with metastatic pancreatic adenocarcinoma (PDA)...
  12. ncbi request reprint An in vivo platform for translational drug development in pancreatic cancer
    Belen Rubio-Viqueira
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:4652-61. 2006
    ....
  13. doi request reprint Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA
    J Clin Oncol 26:5504-10. 2008
    ..Na, a new chemical entity that arrests cancer cells in G(2)/M by modulating mitotic regulatory pathways including polo-like kinase 1 (Plk1)...
  14. ncbi request reprint Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
    Jing Li
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Cancer Biol Ther 6:432-8. 2007
    ..A functional variant of ABCG2 is associated with greater gefitinib accumulation at steady-state and may be relevant to toxicity and antitumor activity of EGFR TKIs...
  15. ncbi request reprint Assessment of celecoxib pharmacodynamics in pancreatic cancer
    Antonio Jimeno
    The Sol Goldman Pancreatic Cancer Research Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, 1650 Orleans Street, Room 1M89, Baltimore, MD 21231, USA
    Mol Cancer Ther 5:3240-7. 2006
    ..The direct pancreatic cancer xenograft model proved to be a valuable tool for drug evaluation and biological studies and showed similar results to those observed in resected pancreatic cancer specimens...
  16. pmc Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma
    Zeshaan A Rasheed
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Natl Cancer Inst 102:340-51. 2010
    ..Aldehyde dehydrogenase (ALDH) activity can identify tumor-initiating cells and normal stem cells from several human tissues. We examined the prognostic significance and functional features of ALDH expression in pancreatic adenocarcinoma...
  17. pmc MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts
    N V Rajeshkumar
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 17:2799-806. 2011
    ..Investigate the efficacy and pharmacodynamic effects of MK-1775, a potent Wee1 inhibitor, in both monotherapy and in combination with gemcitabine (GEM) using a panel of p53-deficient and p53 wild-type human pancreatic cancer xenografts...
  18. pmc Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy
    Ravi Kumar Anchoori
    Division of Chemical Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Med Chem 51:5953-7. 2008
    ..Taken together, our results show that these novel microtubule inhibitors have promising anticancer activity and can be potentially used to overcome paclitaxel resistance in the clinical setting...
  19. pmc The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models
    Masamichi Mizuma
    Departments of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Mol Cancer Ther 11:1999-2009. 2012
    ..Our findings strengthen the rationale for small-molecule inhibition of Notch signaling as a therapeutic strategy in PDAC...
  20. pmc Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Cancer Research Building I, Baltimore, MD, USA
    Cancer Chemother Pharmacol 61:423-33. 2008
    ....
  21. ncbi request reprint C-fos assessment as a marker of anti-epidermal growth factor receptor effect
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Cancer Res 66:2385-90. 2006
    ..In summary, variations in c-fos expression reflect the pharmacologic actions of EGFR inhibitors in in vitro and in vivo models...
  22. ncbi request reprint Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer
    Antonio Jimeno
    Gastrointestinal Cancer Program, The Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Mol Cancer Ther 6:1509-16. 2007
    ..In summary, the novel sulfur benzoylphenylurea SG410 showed activity inversely related to MAPT expression in a preclinical model of pancreatic cancer comparable with that observed with docetaxel, another microtubule-targeting agent...
  23. pmc Fenugreek: a naturally occurring edible spice as an anticancer agent
    Shabana Shabbeer
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Cancer Biol Ther 8:272-8. 2009
    ..Thus, these studies add another biologically active agent to our armamentarium of naturally occurring agents with therapeutic potential...
  24. pmc Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy
    Erlinda E Embuscado
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
    Cancer Biol Ther 4:548-54. 2005
    ..The invaluable tissue resources generated by the success of the GICRMDP will provide an unparalleled resource for study of metastatic pancreatic cancer and of the metastatic process in general...
  25. pmc A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231 1000, USA
    Mol Cancer Ther 8:310-4. 2009
    ..Direct tumor xenografts are a valid platform to test multicompartment therapeutic approaches in pancreatic cancer...
  26. pmc Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
    Georg Feldmann
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Cancer Biol Ther 12:598-609. 2011
    ..Treatment with the cyclin-dependent kinase inhibitor SCH727965 alone or in combination is a highly promising novel experimental therapeutic strategy against pancreatic cancer...
  27. doi request reprint Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Int J Radiat Oncol Biol Phys 86:678-85. 2013
    ..Gemcitabine-erlotinib therapy has demonstrated a survival benefit for patients with metastatic PDAC. Here we report the first phase 2 study of erlotinib in combination with adjuvant chemoradiation and chemotherapy for resected PDAC...
  28. pmc Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer
    Maria C Villarroel
    Corresponding Author Manuel Hidalgo, Clinical Research Program, Spanish National Cancer Research Center CNIO, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain
    Mol Cancer Ther 10:3-8. 2011
    ..Integrating personalized xenografts with unbiased exomic sequencing led to customized therapy, tailored to the genetic environment of the patient's tumor, and identification of a new biomarker of drug response in a lethal cancer...
  29. doi request reprint Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer
    Maria Theresa Mueller
    Clinical Research Programme, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    Gastroenterology 137:1102-13. 2009
    ..Signaling through sonic hedgehog and mammalian target of rapamycin (mTOR), respectively, may be essential for CSC self-renewal and could represent putative targets for novel treatment modalities...
  30. pmc Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 26:4172-9. 2008
    ..We conducted a dose selection study with daily rapamycin (sirolimus) in patients with solid tumors employing a modified continuous reassessment method (mCRM) using real-time pharmacodynamic data as primary dose-estimation parameter...
  31. ncbi request reprint Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
    George Cusatis
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 98:1739-42. 2006
    ..99). The finding suggests that patients with reduced ABCG2 activity due to a common genetic variant are at increased risk for substrate drug-induced diarrhea, with implications for optimizing treatment with such agents...
  32. pmc A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer
    Dan Laheru
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 14:5602-9. 2008
    ....
  33. doi request reprint Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer
    N V Rajeshkumar
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 15:4138-46. 2009
    ..To determine the efficacy of AZD0530, an orally active small molecule Src inhibitor, in human pancreatic cancer xenografts and to seek biomarkers predictive of activity...
  34. pmc A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model
    N V Rajeshkumar
    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Mol Cancer Ther 9:2582-92. 2010
    ..These data provide the rationale to explore the DR5-directed therapies in combination with chemotherapy as a therapeutic option to improve the current standard of care for pancreatic cancer patients...
  35. doi request reprint The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre
    Esther Conde
    Laboratorio de Dianas Terapeuticas, Centro Integral Oncologico Clara Campal, Hospital Universitario Madrid Sanchinarro, Universidad San Pablo CEU, Madrid, Spain
    Histopathology 62:609-16. 2013
    ..To study the ALK translocation in patients with advanced non-small-cell lung carcinomas (NSCLCs) seen at a European cancer centre, and its association with EGFR mutations, KRAS mutations and MET amplification...
  36. ncbi request reprint Developing inhibitors of the epidermal growth factor receptor for cancer treatment
    Viktor Grünwald
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
    J Natl Cancer Inst 95:851-67. 2003
    ....
  37. ncbi request reprint Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Bunting Blaustein Cancer Research Building, Room 1M86, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 819:73-80. 2005
    ..This method was subsequently used to measure concentrations of gefitinib in mice following administration of a single dose of 150 mg/kg intraperitoneally and in cancer patients receiving an oral daily dose of 250 mg...
  38. ncbi request reprint An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
    Maria L Amador
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    Cancer Res 64:9139-43. 2004
    ....
  39. ncbi request reprint Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors
    Charles Erlichman
    Department of Oncology, Mayo Clinic, Rochester, MN 55902, USA
    J Clin Oncol 24:2252-60. 2006
    ....
  40. pmc Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer
    Ignacio Garrido-Laguna
    The Sidney Kimmel Comprehensive Cancer Center and the Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 17:5793-800. 2011
    ....
  41. ncbi request reprint Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration
    Manuel Hidalgo
    Department of Pathology Johns Hopkins School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Mol Cancer Ther 5:1895-903. 2006
    ..This assay is simple to implement and broadly applicable to diverse tumor types in clinical studies with cancer patients and may be useful in the development of targeted anticancer agents...
  42. ncbi request reprint In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 11:8503-11. 2005
    ....
  43. ncbi request reprint Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
    Jing Li
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 13:3731-7. 2007
    ....
  44. pmc DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer
    Christine A Iacobuzio-Donahue
    Department of Pathology, Surgery, and Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Clin Oncol 27:1806-13. 2009
    ..A comprehensive study of pancreatic cancers from patients who have succumbed to their disease has the potential to greatly expand our understanding of the most lethal stage of this disease and identify novel areas for intervention...
  45. ncbi request reprint CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors
    Jing Li
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 98:1714-23. 2006
    ..We prospectively assessed the influence of CYP3A activity on gefitinib disposition and toxicity...
  46. ncbi request reprint Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Pediatr Blood Cancer 49:352-7. 2007
    ..Gefitinib did not induce any significant variation in the levels of the assessed parameters, and none of these determinations showed significant predictive or prognostic value...
  47. ncbi request reprint Targeting mTOR for cancer treatment
    Belen Rubio-Viqueira
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Baunting and Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231, USA
    Curr Opin Investig Drugs 7:501-12. 2006
    ..Several mTOR inhibitors that are currently undergoing clinical development, and the challenges facing the development of inhibitors of this type, will also be discussed...
  48. ncbi request reprint Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors
    Sofia Perea
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Clin Lung Cancer 6:S30-4. 2004
    ..However, it is not known whether these functional mutations are involved in the response of NSCLC to monoclonal antibodies. Further investigation is needed to better predict patients who are more likely to benefit from these drugs...
  49. doi request reprint Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome
    Jose Perea
    Surgery Department, Hospital Universitario 12 de Octubre, Madrid, Spain
    Ann Surg Oncol 18:3285-91. 2011
    ..We evaluated whether early age of onset is a good marker to identify Lynch syndrome, especially retrospectively, and if there is any other feature that could improve this identification...
  50. pmc Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma
    Noriyuki Omura
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 7:1146-56. 2008
    ..Many genes undergo aberrant methylation in human cancers, and microarray platforms enable more comprehensive profiling of aberrant DNA methylation patterns...
  51. pmc A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma
    Barbara Angulo
    Hospital Universitario Madrid Sanchinarro, Laboratorio de Dianas Terapeuticas, Calle Oña 10, Madrid, Spain
    J Mol Diagn 12:292-9. 2010
    ..Sequencing was able to detect KRAS mutations when the mutant DNA represented 10% of the total DNA in 20/74 (27%) of the tumors. When the mutant DNA represented 30% of the total DNA, sequencing could detect mutations in 56/74 (76%)...
  52. ncbi request reprint Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, John Hopkins University, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Expert Rev Anticancer Ther 5:727-35. 2005
    ....
  53. ncbi request reprint Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis
    Wells Messersmith
    Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 4:1381-6. 2005
    ..Colorectal tumors show higher staining of pEGFR and downstream effectors compared to matched normal colorectal tissues...
  54. pmc Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    Sian Jones
    Sol Goldman Pancreatic Cancer Research Center, Ludwig Center and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 321:1801-6. 2008
    ..Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis...
  55. ncbi request reprint Benzoylphenylurea sulfur analogues with potent antitumor activity
    Gurulingappa Hallur
    Division of Chemical Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Med Chem 49:2357-60. 2006
    ..6n was more effective than 1 in causing apoptosis of MCF-7 cells. When compared to other drugs with a similar mechanism of action, 6n retained significant ability to inhibit tubulin assembly, with an IC(50) of 2.1 microM...
  56. ncbi request reprint Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue
    Carlton K K Lee
    Department of Oncology, Johns Hopkins University and Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    Clin Cancer Res 12:2158-65. 2006
    ....
  57. ncbi request reprint Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma
    Jing Li
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 856:198-204. 2007
    ..ON 01910.Na was found stable in plasma at -70 degrees C for at least 1 year. The method was successfully applied to characterize the plasma concentration-time profiles of ON 01910.Na in the cancer patients in the Phase I study...
  58. doi request reprint Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
    Dongweon Song
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 1M89, Baltimore, MD 21230, USA
    Mol Cancer Ther 7:3275-84. 2008
    ..In summary, we show that IPI-504 has potent antitumor activity in pancreatic cancer and identify potential pharmacologic targets using a proteomics and gene expression profiling...
  59. pmc A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry
    Barbara Angulo
    Laboratorio de Dianas Terapeuticas, Faculty of Medicine, Centro Integral Oncologico Clara Campal, Hospital HM Universitario Sanchinarro, Universidad San Pablo CEU, Madrid, Spain
    PLoS ONE 7:e43842. 2012
    ..The specificity was 100% for both antibodies. The LOD of the real-time PCR method was lower than that of direct sequencing. The mutation specific IHC produced excellent specificity...
  60. doi request reprint An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity
    Isabel Ruppen-Cañás
    Proteomics Unit, Spanish National Cancer Research Center, Melchor Fernandez Almagro 3, Madrid, Spain
    Proteomics 12:1319-27. 2012
    ..15 mg) that could be obtained from a needle aspiration biopsy. The described strategy could find application in the clinical arena and be applied to the study of expression of protein variants in disease...
  61. doi request reprint New scaffolds for the design of selective estrogen receptor modulators
    Sonsoles Martin-Santamaria
    Departamento de Quimica, Facultad de Farmacia, Universidad San Pablo CEU, 28668 Boadilla del Monte, Madrid, Spain
    Org Biomol Chem 6:3486-96. 2008
    ..Compound is reported as a novel ERbeta-agonist/ERalpha-antagonist. Two compounds show an interesting antitumour profile towards two pancreatic cancer cell lines and have been selected for in vivo assays...
  62. pmc Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length
    Ming Tseh Lin
    The Department of Pathology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Biotechniques 48:211-8. 2010
    ..Finally, we discuss how contaminating mouse DNA affects next-generation DNA sequencing...
  63. ncbi request reprint Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients
    Jing Li
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21211, USA
    Invest New Drugs 24:291-7. 2006
    ..Variable AAG concentrations observed in cancer patients may affect gefitinib fu with implications for inter-subject variation in drug toxicity and response...
  64. ncbi request reprint Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers
    Collins A Karikari
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Mol Cancer Ther 4:1860-6. 2005
    ..Inhibitors of de novo purine synthesis can be a potential mechanism-based strategy for treatment of biliary tract cancers, one third of which show complete loss of MTAP function...
  65. ncbi request reprint Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, The Bunting Blaustein Cancer Research Building, Room 1M88, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Biochim Biophys Acta 1766:217-29. 2006
    ..This review will discuss the background and currently available preclinical and clinical data...
  66. ncbi request reprint A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 846:1-7. 2007
    ..96. The values for both within day and between day precision and accuracy were well within the generally accepted criteria for analytical methods (<15%)...
  67. pmc A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer
    Wen Wee Ma
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    Transl Oncol 3:373-9. 2010
    ..The pharmacokinetic profile of this combination was also evaluated...
  68. pmc Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Hospital, Baltimore, MD, USA
    J Clin Oncol 26:3503-10. 2008
    ..To examine the efficacy of adjuvant chemoradiotherapy after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PC) in patients undergoing resection at Johns Hopkins Hospital (JHH; Baltimore, MD)...
  69. pmc Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 869:142-5. 2008
    ..0%). This assay was subsequently used for the determination of salirasib concentrations in plasma of cancer patients after oral administration of salirasib at a dose of 400 mg...
  70. ncbi request reprint Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774)
    Viktor Grünwald
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231 1000, USA
    Adv Exp Med Biol 532:235-46. 2003
    ..In summary, Tarceva is a novel inhibitor of the EGFR TK which has shown promising activity in initial studies and is currently undergoing full development as an anticancer drug...
  71. ncbi request reprint Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer
    Maria L Amador
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Clin Colorectal Cancer 4:51-62. 2004
    ..This article will provide a comprehensive review of the current available preclinical and clinical data on EGFR-targeted therapies in colorectal cancer...
  72. ncbi request reprint Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?
    Wells A Messersmith
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 13:4664-6. 2007
  73. ncbi request reprint Design, synthesis and biological evaluation of novel riccardiphenol analogs
    Srinivas K Kumar
    Division of Chemical Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Bioorg Med Chem 13:2873-80. 2005
    ..These results demonstrate that the novel riccardiphenol analog has effective action against human-derived cancer cell in vitro...
  74. ncbi request reprint Targeting mTOR for cancer treatment
    Belen Rubio-Viqueira
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Adv Exp Med Biol 587:309-27. 2006
    ..In conclusion, mTOR inhibitors are promising anticancer agents. Future studies are needed to properly develop these drugs as current cancer treatment...
  75. ncbi request reprint Novel targets in solid tumors: MEK inhibitors
    Wells A Messersmith
    Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 4:831-6. 2006
    ..Whether these predictions will be borne out in clinical testing remains to be seen...
  76. ncbi request reprint Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer
    Antonio Jimeno
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Room 1M88, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Mol Cancer Ther 5:787-96. 2006
    ..The development of new preclinical models is of paramount importance to achieve these goals...
  77. ncbi request reprint Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities
    Wells A Messersmith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 10:6522-7. 2004
    ....
  78. ncbi request reprint Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)
    Manuel Hidalgo
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 1M88, Baltimore, MD 21231, USA
    Semin Oncol 30:25-33. 2003
    ..These studies will hopefully enable us to accurately assess the extent of target inhibition in patients treated with erlotinib and help optimize its clinical use...